BLAUVELT, A.; RICH, P.; SOFEN, H.; LAMBERT, J.; MEROLA, J. F.; LEBWOHL, M.; SCHARNITZ, T.; HOYT, K.; KISA, R. M.; BANERJEE, S. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s49, 2022. DOI: 10.25251/skin.6.supp.49. Disponível em: Acesso em: 19 jul. 2024.